Latest Conference Articles

How the annual college meeting has come to address the rapidly developing field of immunotherapy.

With new immunotherapy data and emerging biologic uses, allergists need to adjust their standards for diagnosis and care in pediatric patients.

Brad Rovin, MD, discusses the NOBILITY study while at Kidney Week and what its impact on patients with lupus nephritis will be.

Kenneth Mahaffey, MD, discussed during Kidney Week the CREDENCE trial and what the link is between the 3 different medical fields.

Investigators present new data from the OLYMPUS and ROCKIES trials during Kidney Week.

Katja Gist, DO, discusses better ways to prevent acute kidney injuries in pediatric patients who have cardiac surgery.

Brad Rovin, MD, of The Ohio State University, discusses during Kidney Week what is needed for better outcomes for patients with lupus nephritis.

Investigators test a potential treatment for the most common hereditary kidney disease during Kidney Week.

Millie Long, MD, MPH, FACG, associate professor of medicine at the University of North Carolina, Chapel Hill, discusses the exciting research she saw at ACG 2019.

Miguel Regueiro, MD and George Khoudari, MD, both of the Cleveland Clinic, discuss predictors of colectomies for IBD-patients.

William Sandborn, MD, chief of the division of gastroenterology at University of California, San Diego, shares updates from ACG 2019 in the field of gastroenterology.

Cash talks ACG 2019 highlights and shares the findings of a poster presentation on a new bowel preparation for colonoscopy.

During the ACG meeting, investigators tested a subcutaneous form of vedolizumab to treat ulcerative colitis.

Miguel Regueiro, MD, of the Cleveland Clinic, talks about some of the medications that treat ulcerative colitis and Crohn's disease at the annual ACG meeting.

With the recent FDA approval, ustekinumab could be the first choice to treat ulcerative colitis.

Millie Long, MD, MPH, FACG, associate professor of medicine at the University of North Carolina, Chapel Hill, shares takeaways from a poster presentation at ACG 2019 on the use of day care and infectious complications in children born to mothers with inflammatory bowel disease.

In a study presented at the ACG 2019 meeting, investigators discuss their groundbreaking work on inflammatory bowel disease.

In a pioneer study, investigators investigate if cannabis users had less incidence of pancreatic necrosis and/or pancreatic/peripancreatic fluid collections.

Investigators test a subcutaneous version of vedolizumab for different durations to treat ulcerative colitis.

At the annual ACG meeting, Carlos Romero-Marrero, MD and Mohammad Alomari, MD discuss what can be done to reduce the drug use rate for high risk patients.

Stephen B. Hanauer, MD, discusses areas of unmet need in gastroenterology and shares what news made a splash at ACG 2019.

Millie Long, MD, MPH, FACG, shares initial updates from the ongoing TARGET-IBD study.

Brooks Cash, MD, delivers his take on areas of unmet need within the gastroenterology field.

Taha Qazi, MD, summarizes his research presented at ACG 2019 comparing objective sleep parameters in minority IBD patients compared to Caucasian IBD patients.

In a study presented at the annual ACG meeting, investigators find that 1L vedolizumab does not impact the effectiveness of subsequent anti-TNF treatment.

Philip Schoenfeld, MD, MSEd, MSc, discusses the benefits of quality indicators in colorectal cancer screening with colonoscopy.

In a poster presented at the annual ACG meeting, investigators estimate the prevalence of medication use by drug class for IBD-patients based on age.

FMT was highly successful for the treatment of recurrent C difficile, and the cure rate was similar between groups who did and did not receive loperamide prior to the procedure.

At the annual ACG meeting, Maria Abreu, MD, explains how drugs like ustekinumab can treat patients with Crohn's disease and patients with ulcerative colitis, while other medications do not work as well in both diseases.

After 44 weeks of maintenance therapy, endoscopic improvement was observed in 43.6% and 51.1% of patients treated with the study drug q12w and q8w, respectively.